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American integumentary leishmaniasis (ATL) is a neglected disease that mostly affects vulnerable populations. Its broad 
spectrum of clinical manifestations is related to the type of immune response produced by the host and the species of Leishmania 
involved. In recent years, the use of medicinal plants has become a therapeutic alternative in the treatment of infectious parasitic 
diseases. This research aimed to evaluate the lymphoproliferative responses of peripheral blood mononuclear cells (PBMCs) 
of patients with cutaneous leishmaniasis (CL) before and after treatment, and healthy individuals. The lymphoproliferative 
response was evaluated in cell culture using stimuli of the dichloromethane fraction (DCM) obtained from Libidibia ferrea, 
Glucantime® and phytohemagglutinin - PHA using a BrdU Cell Proliferation after 72 h of incubation. In cultures treated with 
the DCM fraction, intense induction of lymphoproliferation was observed (p<0.0001), as was also observed in response to the 
PHA mitogen, and there was a significant difference when compared with the conventional treatment (p<0.0135). In the post-
treatment and healthy groups, although the compound induced lymphoproliferation, there was no statistical difference. These 
results suggest that the organic compound played an important inducing role in lymphoproliferation, which highlights the 
importance of continuity involving new studies in order to evaluate its immunomodulatory activity. 
Keywords: Cell proliferation, leishmaniasis, natural products, therapeutic alternative. 
 
Avaliação da linfoproliferação de células mononucleares de pacientes com 
leishmaniose cutânea frente a Libidibia ferrea  
 
Resumo 
A leishmaniose tegumentar americana (LTA) é uma doença negligenciada que acomete majoritariamente populações 
vulneráveis. Seu amplo espectro de manifestações clínicas é relacionado ao tipo de resposta imunológica produzida pelo 
hospedeiro e a espécie de Leishmania envolvida. Nos últimos anos, o uso de plantas medicinais vem sendo uma alternativa 
terapêutica no tratamento de doenças infectoparasitárias. Esta pesquisa teve como objetivo avaliar as respostas 
linfoproliferativas de células mononucleares do sangue periférico (PBMCs) de pacientes com leishmaniose cutânea (LC) antes 
e após tratamento e de indivíduos sadios. A resposta linfoproliferativa foi avaliada em cultura de células frente a estímulos da 
fração diclorometânica (DCM) obtida de Libidibia ferrea, Glucantime® e phytohemagglutinin - PHA utilizando BrdU Cell 
Proliferation após 72h de incubação. Nas culturas tratadas com a fração DCM foi observada em todos os grupos intensa indução 
da linfoproliferação (p<0,0001), apresentando diferença significativa ao comparar com o tratamento convencional no grupo de 
pacientes pós-tratamento (p<0,0135). Estes resultados sugerem que o composto orgânico desempenhou importante ação 
indutora na linfoproliferação ressaltando a importância da continuidade com novos estudos a fim de avaliar sua atividade 
imunomodulatória. 
Palavras-chave: Proliferação celular, leishmaniose, produtos naturais, alternativa terapêutica. 
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American tegumentary leishmaniasis (ATL) is classified by 
the World Health Organization (WHO) as a neglected tropical 
disease (NTD). In Brazil, it is considered a public health 
problem, whose case notification data from the Department of 
Informatics of the National Health System (SINAN, 2019) 
indicated 16,135 confirmed cases of ATL in 2019. The 
northern region had the highest incidence, with 7,123 cases of 
ATL in 2019, with 1,302 cases reported in the state of 
Amazonas. ATL is a disease caused by intracellular protozoa 
of the genus Leishmania (Kinetoplastida, Trypanosomatidae), 
with Leishmania (Leishmania) amazonensis, Leishmania 
(Vianna.) guyanensis and Leishmania (Vianna) braziliensis 
being the main species that cause ATL in Brazil (Brasil, 2017). 
In the Amazon, ATL manifests itself in the cutaneous, 
diffuse cutaneous and mucosal forms, with cutaneous 
leishmaniasis (CL) being the most prevalent in the state of 
Amazonas (Brasil, 2017). CL is characterized by a diversity of 
clinical forms, the lesions of which can be localized or 
disseminated. The variability of clinical presentations depend 
on the species of Leishmania involved in the infection and the 
development of the patient’s immune response (Brasil, 2017). 
Regarding the mechanisms of immune regulation, there is 
a dichotomy between Th1 and Th2, since they induce 
important cytokine profiles that are capable of defining the 
clinical course of infection (Espir et al., 2014). In this context, 
the main human defense against leishmaniasis is its ability to 
adjust the cell-mediated immune response, which is 
demonstrated by lymphoproliferation and the production of 
high levels of IFN-γ and TNF-α, making it capable of 
controlling or even eliminating the parasite. Thus, 
lymphoproliferation is an important evaluation parameter, as it 
demonstrates the ability of a given cell or group of cells to 
proliferate in situations that may be adverse (Teixeira, 
Teixeira, Andrade, Barral-Netto, & Barral, 2006; Bacellar et 
al., 2002). 
 For more than 50 years, the drugs recommended by the 
Brazilian Ministry of Health for treating leishmaniasis have 
been composed of pentavalent antimonials (Sb+5) (Carvalho et 
al., 2019). Despite their effectiveness, Sb+5 presents a number 
of problems, such as parenteral administration, long duration 
of treatment, high toxicity and high cost. Thus, many patients 
who contract leishmaniasis abandon treatment, which is a 
factor that favors the appearance of resistant strains (Pradhan, 
Schwartz, Patil, Grabbe, & Goldust, 2021). 
Due to the high toxicity of the drugs that are currently used, 
new therapeutic alternatives have been studied, and Libidibia 
ferrea is one of the candidates. It is a plant that belongs to the 
Fabaceae family, and is popularly known in Brazil as “pau-
ferro” or “jucá”. L. ferrea has a multiplicity of therapeutic uses 
and its different plant parts are used in the treatment of various 
diseases. Therefore, given its medical importance, the 
Brazilian Ministry of Health has included this species in the 
National List of Important Medicinal Plants for the Health 
System and indicates that it has analgesic, antipyretic, anti-
inflammatory and/or antispasmodic (Brasil, 2006), and healing 
and antioxidant properties (Carvalho, Sampaio, Araújo, Pinto, 
& Rocha, 2016; Falcão et al., 2019). 
Antileishmanial activity was observed by Comandolli-
Wyrepkowski et al. (2017), who confirmed that L. ferrea 
presented efficiency in the treatment of CL in in vitro and in 
vivo experiments. In this sense, considering the therapeutic 
relevance of L. ferrea, this study aimed to evaluate the action 
of a fraction obtained from the methanolic extract of L. 
ferrea on the lymphoproliferation of PBMC of people 
exposed to Leishmania sp. and compare it to those not 
exposed, for the purpose of providing subsidies for new 
Leishmaniasis treatment strategies. 
 
Materials and Methods 
 
Plant material and fractionation 
Samples of the fruit of L. ferrea were collected in 
Manaus, Amazonas, Brazil (3º 4’ 34”S 60º 0’11” W). These 
were deposited in the Herbarium of the National Institute for 
Amazonian Research – INPA and identified under the 
number 246150. The collected fruits were sorted and, after 
removing the seeds, were dried, pulverized and extracted 
with the solvents hexane and methanol (Comandolli-
Wyrepkowski et al., 2017). The dichloromethane fraction 
(DCM) of the L. ferrea extract was obtained by liquid-liquid 
partition. An aliquot of 20 g of methanolic extract solubilized 
in 200 mL of H2O:MeOH (9: 1) was used and extracted three 
times with each of the solvents used in the partition (hexane 
and dichloromethane). After this process, the fraction was 
concentrated in a rotary evaporator (YAMATO®). 
 
Ethical aspects 
This work was approved by the Ethics Committee for 
Research with Human Beings (CEP) of the Federal 
University of Amazonas (UFAM) - CAAE/UFAM: 
29406319.2.0000.5020. All the volunteers who agreed to 
participate in the study signed the informed consent form. 
 
Sample population 
The biological samples used in this study were obtained 
from 30 people from the municipality of Rio Preto da Eva 
(2° 41' 55'' S, 59° 42' 3'W), Amazonas state, Brazil, who 
sought treatment at a basic healthcare unit (UBS), in the 
period from March to June 2020. The participants in this 
study were divided into three groups: before treatment, after 
treatment and negative control, according to Table 1.  
 All the primoinfected patients underwent a physical 
examination and the diagnosis for CL was based on the 
detection of Leishmania sp. amastigotes, from scarification 
of the inner edge of the lesion and smears stained with rapid 
the Panotic Kit (Laborclin™). Samples of the edge of the 
lesion of each patient were inoculated in NNN (Neal, Novy 
and Nicolle) culture media for parasitological confirmation 
of promastigote forms of the parasite. 
 
Blood sampling and PBMC extraction 
Around 8 mL of heparinized blood was collected from all 
study participants. The blood samples were transferred to 
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centrifuge tubes, diluted in complete RPMI (Roswell Park 
Memorial Institute) medium at a 1:1 ratio and had 8 mL 
Histopaque™ 1077 carefully added. The tubes were 
centrifuged at 2,200 rpm for 30 minutes. The peripheral 
mononuclear cells (PBMCs) were collected and transferred to 
centrifuge tubes, washed twice with RPMI medium, and then 
centrifuged at 1,800 rpm for 10 minutes at 4 ºC. The PBMCs 
were resuspended in 1 mL of complete RPMI medium and 
counted in the Neubauer chamber with the aid of Trypan blue. 
The concentration of PBMCs was adjusted to 2 x 105 cells/mL 
in complete RPMI medium. 
 
Table 1. Participants in the study from Rio Preto da Eva, 
Amazonas, Brazil organized by group and the inclusion criteria 
used in the research. 
Group Inclusion criteria 
Before treatment 
(primoinfection) 




Patients post Glucantime® treatment for 
cutaneous leishmaniasis with healed lesions. 
Blood collection of this group was performed 
after full healing of the lesion and clinical 
evaluation to ensure that the lesion was no 
longer active, at least 30 days and up to 12 
months after treatment. 
Negative 
control  
Healthy individuals, without clinical 
manifestations or lesions caused by 
Leishmania spp. 
The healthy individuals were from the 
metropolitan area of Manaus, and 
epidemiological questionnaire was applied to 
ensure that these individuals had not been in 
an endemic area in recent months. 
The number of participants in each group was n = 10. 
 
In vitro cell stimulation assays 
The PBMCs were transferred to culture microplates of flat-
bottomed 96-well plates; each well containing 100 µL/PBMC 
[2×105]. The tests were individually carried out with the PBMC 
samples from each participant. The wells of the microplates, 
with 100 µL/well fr each test substance (final volume of 200 
μg/well), were organized in triplicate as follows: wells 
containing cells stimulated with phytohemagglutinin-PHA [10 
μg/mL], considered the positive control for 
lymphoproliferative response; wells without stimulation (with 
only RPMI medium) were considered the negative control; 
wells with cells treated with Glucantime® [100 μg/mL]; and 
wells with cells treated with the DCM fraction [120 μg/mL]. 
Prior to this, both substances were diluted in RPMI 
medium, and the DCM fraction was first dissolved in DMSO-
dimethylsulfoxide (CH₂)₂SO (1%). The PBMCs were 
incubated for 72 h at 37 °C (5% CO2; 95% humidity) and, after 
18 hours of incubation, BrdU (5-bromo-2'-deoxyuridine) [10 
μM/mL] was added. An ELISA (enzyme-linked 
immunosorbent assay) colorimetric test was performed 
according to the manufacturer’s instructions (BrdU Cell 
Proliferation ELISA Kit, Biotrak, Amersham, UK). 
Lymphoproliferation was evaluated based on the 
quantification of BrdU incorporation, by means of the 
average increase in optical density through 
spectrophotometry (absorbance of 450 nm). Estimates of cell 
proliferation were determined as a relative value between the 
arithmetic mean of positive and negative control triplicates 
(white, well with RPMI medium), in relation to wells with 
stimulated cells.  
 
Statistical analysis 
The statistical analysis was carried out using GraphPad 
Prism® software v.6.0 for Windows, for which the 
significance (p<0.05) was calculated using parametric tests. 
A one-way ANOVA statistical test was used for comparisons 
among groups of study subjects and the Tukey test was used 
for comparisons among the drug treatments. 
 
Results and Discussion 
During the treatment, epidemiological investigations and 
clinical evaluations were performed on the 20 patients 
diagnosed with CL. Of these, ten were positive direct 
examination primoinfected patients, and ten were patients 
who had achieved clinical cure, which was evaluated 
according to wound healing, after treatment with 
Glucantime®. There was a predominance of CL in males 
(85%), and 76.47% were in the age group between 19 and 56 
years. The higher prevalence of males, who are young and 
are involved in forest extractivism are part of the 
epidemiological profile of ATL in the Brazilian Amazon 
(Figueira et al., 2017; Hernández & Núñes, 2019). 
Regarding the CL lesions, 91.30% were ulcerated 
lesions, with a mean size of 2.0 cm, 62.86% of which were 
located in the lower limbs and 13.04% in the upper limbs and 
trunk (Figure 1). Figueira et al. (2017) also described a 
higher prevalence of ulcerated lesions of the CL, as well as a 
high frequency of lesions in the lower limbs. However, the 
study by Hernández & Núñes (2019), also conducted with 
patients living in the municipality of Rio Preto da Eva, in the 
period from 2014 to 2016, found a lower number of lesions 
in the lower limbs. In contrast, Sampaio et al. (2009) and 
Hernández and Núñes (2019) noted a higher frequency of 
patients with CL lesions in the upper limbs, in the 
municipalities of Rio Preto da Eva and Tefé in the Amazonas 
state, and in Brasília, DF.  
Of the 30 subjects involved in this study, mononuclear 
cells from 21 participants (7 samples/group) were analyzed 
in vitro. The lymphoproliferative response was expressed in 
high rates (≥60%) (Figure 2) of PBMCs in the primoinfected 
(p=0.0873) (Figure 2A), post-treatment (p=0.0135) (Figure 
2B) and negative control (p=0.0624) (Figure 2C) groups with 
the stimulus by the DCM fraction, conventional treatment 
with Glucantime® and PHA mitogen. 
The lymphoproliferation of PBMC was strongly positive 
(100%) and significant in response to PHA mitogen (Figure 
2) and was verified in all groups of participants. PHA 
mitogen is commonly used as a lymphoproliferation 
enhancer and has been used in other studies (Reis et al., 
2009; Mohammadi, Duthie, Reed, Javadi, & Khamesipour, 
2021). 
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Figure 1. Clinical aspects of lesions in male patients 
primoinfected with cutaneous leishmaniasis (CL) treated in 
Rio Preto da Eva, Amazonas, Brazil, during March to May 
2020. IM: Registration code.  
 
Figure 2. PBMC lymphoproliferation of participants evaluated 
in Rio Preto da Eva, Amazonas state, Brazil, during March and 
May 2020. A - primoinfected patients with cutaneous 
leishmaniasis; B - post-treatment cutaneous leishmaniasis 
patients; C - healthy people without cutaneous leishmaniasis. 
DCM: dichloromethane fraction; PHA: phytohemagglutinin. 
Vertical lines represent standard error. *Horizontal lines 
represent statistical significance between treatments (p<0.005).  
 
The PBMC cultures from all the groups showed a 
significant lymphoproliferative response (≥77%; p<0.0007) to 
the dichloromethane fraction (DCM) (Figure 2). In particular, 
the group of post-treatment patients, in particular, presented 
almost 100% proliferated cells induced by DCM. Thus, the 
DCM fraction induced more cell proliferation than 
Glucantime®, which was different to that observed for the 
primoinfected and negative control groups, since the values 
between the substances were equivalent. 
This result of expressive lymphoproliferation may be 
related to the therapeutic biological potential of the fraction of 
L. ferrea obtained, whose antileishmanial activity was 
confirmed against L. (L.) amazonensis and L. (V.) guyanensis 
and did not present cytotoxic effects in murine macrophages 
(Comandolli-Wyrepkowski et al., 2017). To date, the 
mechanism of action of the pharmacological components of 
L. ferrea in vivo is not yet known. However, promising 
effects of L. ferrea for the treatment of CL were observed by 
Comandolli-Wyrepkowski et al. (2017), when submitting 
Golden hamsters (Mesocricetus auratus) that were infected 
with L. (L.) amazonensis and L. (V.) guyanensis to topical 
treatment with a hydrogel containing the DCM fraction of L. 
ferrea. Control of the growth of the CL lesions in animals 
and low parasitic load in culture analyses were noted after 
treatment. 
The phytochemical prospecting of the extract of L. ferrea 
showed the presence of phenolic compounds and flavonoids 
in greater evidence (Comandolli-Wyrepkowski et al., 2017). 
Phenolic compounds are recognized as being involved in 
anti-inflammatory and antioxidant activity, and act directly 
on specialized cells of the immune system (Hakime-Silva et 
al., 2013). Vila-Nova et al. (2012) demonstrated 
leishmanicidal activity of the phenolic compound coumarin 
(scoporone) isolated from Platymiscium floribundum, and of 
the flavonoids (rutin and quercetin) that were isolated from 
Dimorphandra gardneriana. These are both plants that are 
native to the Caatinga biome of Brazil, and in this case were 
against Leishmania infantum, which are the protozoa that 
cause visceral leishmaniasis. These compounds were able to 
inhibit the enzyme acetyl-cholinesterase (AChE) and, 
consequently, disrupt the biosynthesis of 
phosphatidylcholine, an essential constituent of the surface 
membranes of the parasite. 
Among some of the important phenolic compounds 
found in L. ferrea is gallic acid. Associating these phenolic 
compounds and amphotericin B, Alves (2019) demonstrated 
the activation of macrophages and a reduction in amastigotes 
through macrophage, indicating therapeutic action and 
activation of the immune response, and leading to the healing 
of lesions in Mus musculus lineage BALB/c. Some studies 
with herbal compounds, such as Campsiandra laurifolia 
(Chagas, Henrique Müller, Soares & Garcez, 2010), 
Portulaca hirsutissima and Portulaca werdermannii (Costa 
et al., 2007), Nelumbo nucifera (Khan et al., 2016), did not 
demonstrate direct action on the parasitic agent, but rather, 
as potential anti-inflammatory treatments with high 
immunomodulatory capacity in Leishmania sp. infections.  
Considering the PBMCs exposed to Glucantime®, all the 
groups had a high rate of lymphoproliferation in response to 
Glucantime® (≤70%; p<0.001) (Figure 2). The treatment of 
CL with antimonials promotes changes in the immune 
response of the host, corroborating with the modulation of 
the immune system, increased the ability of direct 
destruction or gradual elimination of the parasite (Brelaz-de-
Castro et al., 2012). The rate of cell proliferation of the 
samples of PBMC exposed to Glucantime® from post-
treatment subjects (73%) (Figure 2B) was reasonably lower 
than that of the samples of the primoinfected (79%) patients 
(Figure 2A). These data corroborate the findings of Toledo 
et al. (2001), who also observed a decrease in 
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stimulated with total antigen of L. (V.) braziliensis. The authors 
pointed out that in an in vivo study, T cell stimulation is 
expected to decrease as treatment progresses to cure, since the 
reduction in parasitic load can cause the number of responsive 
T cells to decrease. It is worth remembering that in both 
studies, blood collection of post-treatment patients was 
performed at least 30 days after the end of Glucantime® 
treatment. 
The toxicity of meglumine antimoniate goes far beyond the 
adverse effects on the vital organs of CL patients while being 
treated. Lopez (2015) observed that antimoniate interfered in 
the process of cell proliferation, in addition to contributing 
cytotoxic, genotoxic and mutagenic effects in human 
leukocytes exposed to different concentrations of 
Glucantime®. Given this, the combination therapy of potential 
drugs and antimoniate have numerous advantages, such as 
reduced toxicity, ease in the treatment regimen and reduced 
development of resistance to this drug. 
Lymphoproliferation is considered an important factor in 
the control of infection or even in the elimination of 
Leishmania sp. (Brasil, 2017). Therefore, the discovery of 
phytopharmaceuticals with immunomodulatory capabilities 
are crucial for the development of alternative treatments or for 
combination with recommended drugs, in order to provide a 
potential synergism and therapeutic success in treating 
leishmaniasis. This study contributes to a more diligent look at 
the importance of the immunomodulatory effect of L. ferrea 
that may favor the healing of lesions in patients with CL. 
However, for the best elucidation of the regulation of 
inflammation induced by the DCM fraction, it is necessary to 




These findings suggest that the organic fraction DCM 
induced stimulatory action on activation and 
lymphoproliferation when incubated with the PBMC of patients 
before and after treatment for CL, which may, at least in part, 
be due to an immunomodulatory response.  This 
immunomodulatory response needs to be highlighted and better 
investigated in future trials in order to strengthen the data 
presented here in order to demonstrate which molecular 
mechanisms are involved and the stimulatory effect of the 
immune response caused by the dichloromethane fraction of L. 
ferrea, a phytopharmaceutical candidate for the alternative 
treatment of cutaneous leishmaniasis. 
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